DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 17, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 RBC Capital Markets Global Healthcare Conference on Wednesday, February 24 at 11:00 AM ET (4:00 PM GMT). The conference is being held at the New York Palace Hotel in New York, NY.
Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
